Safety Profile of Antimuscarinics in Elderly Dementia Patients
Tuesday, July 20, 2021
12:00 pm - 1:00 pm
Dementia and Overactive Bladder (OAB) are one of the most common comorbid conditions affecting older patients. Pharmacological management of OAB involves the use of antimuscarinic drugs. Although antimuscarinics are effective, they vary in their safety and tolerability profiles due to differing selectivity for muscarinic receptor subtypes.
Some of the antimuscarinics like oxybutynin, tolterodine, trospium and fesoterodine are non-selective as they have an affinity for all muscarinic receptors, and others like darifenacin and solifenacin are selective due to their high affinity for M2/M3 receptors. Our population-based research involving a national cohort of elderly Medicare beneficiaries evaluated the safety profile of antimuscarinics. The study involved a propensity score-matched cohort design to adjust for the selection bias across antimuscarinic classes using the robust Cox proportional hazards models.
This presentation will share the findings of the comparative safety of antimuscarinic use among older dementia patients with OAB. The research was funded by the National Institute on Aging.
About the Speaker
Rajender R. Aparasu, Ph.D., FAPhA, is the Mustafa and Sanober Lokhandwala Endowed Professor and chair of the Department of Pharmaceutical Health Outcomes and Policy at the UH College of Pharmacy.